Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lydia J. Hammond
Observed names:
L. Hammond,
Lydia Hammond
Institutions:
Bristol-Myers Squibb (United States),
Taiho Pharmaceutical (Japan),
National Comprehensive Cancer Network
Observed institutions:
Bristol-Myers Squibb (United States),
Taiho Pharmaceutical (Japan),
National Comprehensive Cancer Network
OpenAlex ID:
A5000630229
Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
2019
·
Robert A. Swarm
, Judith A. Paice
, et al.
·
Journal of the National Comprehensive Cancer Network
·
624
PDF
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
2019
·
Martin S. Tallman
, Eunice S. Wang
, et al.
·
Journal of the National Comprehensive Cancer Network
·
419
NCCN Guidelines Insights: Kidney Cancer, Version 2.2020
2019
·
Robert J. Motzer
, Eric Jonasch
, et al.
·
Journal of the National Comprehensive Cancer Network
·
285
PDF
Guidelines Insights: Hepatobiliary Cancers, Version 2.2019
2019
·
Al B. Benson
, Michael I. D’Angelica
, et al.
·
Journal of the National Comprehensive Cancer Network
·
269
PDF
NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018
2018
·
Michael B. Streiff
, Bjorn Holmstrom
, et al.
·
Journal of the National Comprehensive Cancer Network
·
242
PDF
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), ZD1839 (‘Iressa’), in combination with 5-fluorouracil (5-FU) and leucovorin (LV), in advanced colorectal cancer (ACRC)
2001
·
L. Hammond
, J. Figueroa
, et al.
·
European Journal of Cancer
·
27
Show more works
View as search
Works count:
6
Citation count:
1,865
H-index:
6
I10-index:
6
Year
Topic
Type